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Vaccination using Cytomegalovirus (CMV) vectors have recently shown promising results in conferring 
protection in non-human primates against SIV and Mycobacterium tuberculosis infection (1-3). Since CMV 
vectors can stimulate the production of high concentrations of systemic effector memory T-cells, CMV vectors 
(containing the appropriate insert) have the potential to clear SIV/HIV and Mycobacterium tuberculosis infection, 
provided administration occurs at the onset of infection (1, 3).  Despite the promising animal data, CMV vectors 
are prone to potency loss (i.e., degradation) by freeze-thaw and storage at 2-8°C. In this study, we wished to 
develop formulations with increased freeze-thaw and liquid stability for a recombinant human CMV vector 
(rHCMV-1) for use in initial clinical trials including i) reduce vector potency loss to <0.5 log after 1 freeze-thaw 
cycle and ii) reduce vector potency loss to <0.5 log after 4 hours at 2-8°C storage. To achieve these goals, we 
screened a library of ~50 pharmaceutical excipients and evaluated their effect on vector potency after 3 freeze-
thaw cycles or incubation at 4°C for several days.  We found that certain additives completely protected rHCMV-
1 against freeze-thaw mediated potency loss.  With regards to liquid stability, we found certain additives slowed 
the rate of rHCMV-1 titer loss when stored at 4°C.  After screening various excipient combinations, we evaluated 
three candidate formulations and benchmarked them against the bulk drug substance (BDS) formulation buffer 
and another published formulation (4).  The candidate formulations were significantly more stable than the 
formulations used for benchmarking in terms reducing rHCMV-1 titer loss due to freeze-thaw and incubation at 
4°C for up to 30 days.  Despite providing greater stability than the current BDS formulation buffer, rHCMV-1 titer 
loss was still observed at 4°C as a function of incubation time, which suggests further stabilization (i.e., 
lyophilization) is likely necessary for longer term development. This study highlights the utility of empirical design 
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